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RESEARCH ARTICLE
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Abstract
HER2 assessment is routinely used to select patients with invasive breast cancer that might
benefit from HER2-targeted therapy. The aim of this study was to validate a fully automated
in situ hybridization (ISH) procedure that combines the automated Leica HER2 fluorescent
ISH system for Bond with supervised automated analysis with the Visia imaging D-Sight
digital imaging platform. HER2 assessment was performed on 328 formalin-fixed/paraffin-
embedded invasive breast cancer tumors on tissue microarrays (TMA) and 100 (50 select-
ed IHC 2+ and 50 random IHC scores) full-sized slides of resections/biopsies obtained for
diagnostic purposes previously. For digital analysis slides were pre-screened at 20x and
100x magnification for all fluorescent signals and supervised-automated scoring was per-
formed on at least two pictures (in total at least 20 nuclei were counted) with the D-Sight
HER2 FISH analysis module by two observers independently. Results were compared to
data obtained previously with the manual Abbott FISH test. The overall agreement with Ab-
bott FISH data among TMA samples and 50 selected IHC 2+ cases was 98.8% (κ = 0.94)
and 93.8% (κ = 0.88), respectively. The results of 50 additionally tested unselected IHC
cases were concordant with previously obtained IHC and/or FISH data. The combination of
the Leica FISH system with the D-Sight digital imaging platform is a feasible method for
HER2 assessment in routine clinical practice for patients with invasive breast cancer.
Introduction
Breast cancer is the most common form of cancer in women with an incidence of 464,000 cases
in Europe in 2012 [1]. The development and progression of breast cancer is influenced by the
human epidermal growth factor receptor-2 (HER2) [2–3]. Specifically, amplification of the
HER2 gene (ERBB2) is found in approximately 10% to 20% of invasive breast carcinoma [4–5]
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and results in the overexpression of HER2 protein and is associated with a poor prognosis [6–
8]. Because of the high incidence of HER2 overexpression, HER2 was considered a candidate
for targeted therapy. Treatment with the monoclonal antibody trastuzumab inhibits the prolif-
eration of tumor cells that overexpress HER2 [9–11] and thereby significantly increases the
survival of HER2-positive patients [12–13]. Prediction of HER2-directed therapy is determined
by assessing HER2 status with immunohistochemistry (IHC) and reflex testing of IHC++ with
in situ hybridization (ISH) techniques [4–5]. The successful implementation of HER2 testing
in medical practice is well established. All women who received trastuzumab had a HER2 test,
and more than 95% of these women had a positive HER2 status in a cohort of lymph node-pos-
itive breast cancer or 2+ cm tumors in size diagnosed between 1999 and 2007 enrolled at eight
Cancer Research Network study sites across the United States [14]. However, the inaccuracy of
HER2 testing remains a major issue. Approximately 10–20% of HER2 tests performed in local
laboratories could not be confirmed by a central laboratory [15, 16]. In addition, in about 40%
of breast cancer patients with a HER2 borderline test result, the clinical practice guidelines
were not followed, in that reflex FISH testing was not offered to these patients to clarify HER2
status [14]. As a consequence, patients with a false-positive test or a fraction of patients with
only a borderline IHC test are treated at high costs and potential cardiotoxicity without having
benefit from their therapy.
In most laboratoriesHER2 ISH testing remains a time-consuming and technically challeng-
ing manual molecular diagnostic assay because of the risk for human processing errors and
subjective interpretation. The American Society of Clinical Oncology (ASCO) published a
guideline for HER2 testing with recommendations to improve the standardization of the assay
by the automation of the total procedure, from staining up to analysis [15, 17]. Recently, this
has been partly achieved by the development of fully automated staining procedures for both
fluorescent- [18] and bright-field ISH [19–20]. However, the standardization ofHER2 gene sta-
tus testing could be further improved by automating the analysis of the slides. This will intro-
duce a more objective classification ofHER2 gene status. The FISH analysis systems described
by Netten et al., CytoFISH, FishJ and MetaSystems have shown the ability to standardizeHER2
analysis by automatic counting of fluorescent signals [21–24]. These digital analysis systems
are based on automated nucleus selection, followed by automated spot counting and optionally
human corrections can be made. Automated analysis was highly concordant with manual anal-
ysis [23–24]. Recently, Visia imaging has developed the D-Sight digital imaging platform
which integrates both the generation of digital images and automated image analysis.
The objective of this study was to validate the standardized detection ofHER2 gene status
using a fully automated ISH procedure, combining the automated Leica HER2 fluorescent in
situ hybridization (FISH) staining system for Bond and subsequent supervised automated anal-
ysis with the Visia imaging D-Sight digital imaging platform. Validation was achieved by com-
paring these data with data obtained previously by manual analysis of DAKO IHC, Abbott
FISH using tissue microarray (TMA; n = 328) and full-sized slides (n = 100) from formalin-
fixed paraffin-embedded (FFPE) tissue specimens of invasive breast cancer.
Materials and Methods
Tissue specimens
The validation process was divided in three phases and in total formalin-fixed paraffin-embed-
ded (FFPE) tissue specimens of 448 invasive breast cancer cases were analyzed (see Table 1).
Firstly, the use of automated Leica FISH staining and the suitability of the settings of the
D-SightHER2 FISH analysis module for digital analysis was tested on 20 full-sized tissue slides.
Secondly, technical validation was set up on a larger series of cases using Tissue Micro Arrays
Automated Staining and Digital Analysis of HER2
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(TMAs). For TMA design paraffin blocks from the University Medical Center Groningen
(UMCG) and Isala Klinieken Zwolle were used as reported by Dekker et al. [25]. From each
tumor three cores with a diameter of 0.6 mm were collected. Thirdly, validation on clinical rou-
tine specimens was performed on 100 resections/full-sized slides or biopsies (18%) consecu-
tively collected at Pathology Friesland (divided in 50 selected DAKO IHC 2+ cases and 50
unselected cases with different IHC scores. The tissue blocks that were used in this study were
all collected during routine diagnostics. According to Dutch law, these can be freely used after
anonymizing the tissues, provided these are handled according to national ethical guidelines
(‘Code for Proper Secondary Use of Human Tissue’, Dutch Federation of Medical Scientific
Societies).
Fully manual HER2 testing using the DAKO HercepTest and Abbott
HER2 FISH test
As reference method we used a fully manual HER2 testing procedure (both staining and analy-
sis). Firstly, immunohistochemistry (IHC) for HER2 was performed manually with the DAKO
HercepTest (Glostrup, Denmark) at Pathology Friesland, as described previously [26]. Second-
ly,HER2 gene status was determined for TMA and IHC 2+ cases using a conventional manual
procedure with the PathVysionHER2 DNA Probe kit, (Abbott Molecular, Illinois, United
States) performed in the routine ISO15189-certified laboratory of Molecular Pathology in the
UMCG (referred to as Abbott FISH). After dewaxing, unmasking of the target nucleic acids at
120°C for 7 min in TRIS/EDTA pH9.0 buffer in pressure cooker, pretreatment with RNase at
37°C for 10 min and with pepsin at 37°C for 1 hr, denaturation and hybridization were per-
formed according the manufacturer´s instructions. Data on Abbott FISH will be reported sepa-
rately [27].
Manual FISH analysis started by scanning of the slide/core for areas of amplification. In
full-sized slides with IHC 2+ scores a pathologist marked the area of interest. Scoring for in situ
hybridization was performed by two independent observers according to the American Society
of Clinical Oncology (ASCO) guidelines 2007 [15]. Discordant cases were scored by a third ob-
server. The HER2 and chromosome 17 (CEP17) signals were counted in at least 20 non-over-
lapping nuclei and the ratio between HER2 and CEP17 was calculated. When the ratio
was< 1.8, theHER2 gene status was defined as non-amplified, while a ratio2.2 was consid-
ered asHER2 gene amplification. Ratios between 1.8 and 2.2 were counted as equivocal and an
additional number of 20 nuclei were scored. When this yielded a ratio<2.0, theHER2 gene sta-
tus was defined as non-amplified and a ratio2.0 was classified as HER2 gene amplified.
Table 1. Characteristics tested tissue specimens of patients with invasive breast cancer with LeicaHER2 FISH.
Validation N Tissue specimen Pathology lab IHC score (DAKO) Data ISH method
Settings automated 20 Resection Groningen 2007 5x 0 Abbott
staining and analysis 5x 1+ Abbott
5x 2+ Abbott
5x 3+ Abbott
Technical 328 Resection TMA Groningen / Zwolle 2007 Variable Abbott
Clinical 50 Resection / biopsy Friesland 2011 Selected 2+ Abbott
50 Resection / biopsy Friesland 2012 (consecutive) Unselected (0–3+) 2+ Abbott
IHC, immunohistochemistry; TMA, tissue micro array.
doi:10.1371/journal.pone.0123201.t001
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Fully automated Leica HER2 FISH staining and supervised automated
analysis
In this study, we investigated the performance of a fully automated HER2 gene testing proce-
dure (both staining and analysis; referred to as Leica FISH). Fully automated FISH was per-
formed on the Leica Bond slide-staining system using the FISH HER2 staining kit (TA9217)
from Leica Microsystems (Newcastle, UK) according to manufacturer’s instructions with ex-
ception of adjustments to optimize pretreatment conditions. It is a fluorescent in situ hybrid-
ization product and contains PathVysion + LSI +HER2/CEP17 FISH probes supplied by
Abbott Molecular Inc. The LSIHER2 probe is a 190 Kb SpectrumOrange directly labeled fluo-
rescent DNA probe for theHER2 locus (17q11.2-q12) and the CEP17 DNA probe is a 5.4 Kb
SpectrumGreen directly labeled fluorescent DNA probe specific for the alpha satellite DNA se-
quence at the centromeric region of chromosome 17 (17p11.1-q11.1).
Breast cancer tissue specimens were routinely processed and sectioned into 4 μm slides. Be-
fore staining, slides were incubated at 60 °C for one hour and Enzyme 5 (i.e. proteinase K) was
freshly prepared by dilution (1:300) of Enzyme Concentrate 2 of the Leica HER2 FISH staining
system in Enzyme diluent. All other components are ready-to-use. Prior and after use the stain-
ing system was stored at 2–8 °C. The default automated staining protocol was as follows:
dewaxing, unmasking of the target nucleic acids at 97°C for 25 min (adjusted to 30 min in this
study) with Bond epitope retrieval solution 1 (i.e. citrate buffer), pretreatment with Enzyme 5
at 37°C for 25 min (adjusted to 5 min in this study), denaturation at 95°C for 10 min, hybrid-
ization with probes at 37°C for 12h, stringency washing with Post hybridization wash solution
2 at 48°C for 4 min, dehydration (2x alcohol 96% and air-dried) and finally slides were
mounted manually in vectashield with DAPI (1:1 diluted in vectashield) and sealed with color-
less nail-polish. Stained sections were stored at -20 °C in the dark until evaluation to prevent
fading of the fluorescent signals. Incubation times of heat induced epitope retrieval and enzyme
treatment were adapted because default setting resulted in suboptimal staining of the slides
with no/weak signals for analysis.
In this study, we evaluated theHER2 gene status of 380 TMA cases for Leica FISH. Fifty-
two TMA cases yielded incomplete ISH scores due to absence of tissue cores, folding of tissue
cores, too low amounts of invasive breast cancer cells for scoring or because no FISH signals
were detected (only three cases). Therefore, data of 328 TMA cases could be compared with
Abbott FISH. These staining issues were not encountered with full-sized slides or biopsies (=
clinical practice).
Analysis was performed by supervised automated scoring with the Visia imaging D-Sight
digital imaging platform (exclusively distributed in Europe by Menarini Benelux). At first,
slides were scanned at 4x magnification to obtain an overview of the tissue specimen. In case of
slides with IHC 2+ scores the marked area of interest (invasive tumor identified by a patholo-
gist) was visible. To account for possible heterogeneity, slides were pre-screened at 20x magni-
fication in the SpectrumOrange channel setting and checked for HER2 gene amplification.
This was repeated at 100x magnification on a selected area of interest and all fluorescent signals
were checked for signal intensity using the SpectrumOrange, SpectrumGreen and DAPI filter
channels. At least 4 areas of interest were selected for analysis and images were taken automati-
cally by the monochrome camera for all fluorescent signals using Z-stack acquisition (13
stacks/planes, distance 0.5 μm). Captured images from different focus planes were combined
generating a picture with all signals clearly detectable after removal of unspecific background.
Supervised automated scoring was performed on at least two pictures (in total at least 20 nu-
clei were counted) with the D-Sight HER2 FISH analysis module (software version 2011 1.3.15;
[28]) and the ratio between HER2 and CEP17 was generated. Automated nucleus selection and
Automated Staining and Digital Analysis of HER2
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spot counting of the red (HER2) and the green (CEP17) signal was evaluated and corrected by
the observer if needed. Nuclei without red and green signals were automatically excluded dur-
ing the nucleus selection step by the image analysis software. The observers need to indicate
the areas of interest in the tissue on the slide before the D-Sight analysis module will count
HER2 and CEP17 copies per selected area automatically. Heterogeneity will be observed by
analysis of the data by the observers (= supervised automated scoring). Fig 1 shows an example
of the latest software version (2012 2.1.2) of the D-Sight HER2 FISH analysis module.
Scanning and scoring was conducted by two independent observers and upon discordance a
third analysis was made by the two observers together to obtain a final (consensus) score. The
quality of the Leica FISH was monitored by inclusion of an internal control in each run and
consisted of a TMA of earlier analyzed invasive breast cancer tumors with different expression
of HER2.
The HER2 gene status determined by the available Visia imaging D-SightHER2 FISH analy-
sis module (software version 2011 1.3.15) is based on the FISH scoring criteria according to
ASCO guideline 2007 [15] as described in the previous section. A new software version (2.5.0)
based on the recently updated ASCO guideline [17] will be available in December 2014 (per-
sonal communication with Menarini Benelux). This means that the data in the present study
Fig 1. The design of the D-SightHER2 FISH analysis module (software version 2012 2.1.2). “Pictures”: at least 4 areas of interest are selected for
analysis and pictures are taken automatically. Captured images from different focus planes are combined generating a picture with all signals clearly
detectable after removal of unspecific background. “Objectives and tools”: automated nucleus selection and spot counting of the red (HER2) and the green
(chromosoom 17 = CEP17) signal is evaluated and corrected by the observer if needed. “Analysis”: supervised-automated scoring is performed on at least
two pictures and the ratio betweenHER2 andCEP17 was generated.
doi:10.1371/journal.pone.0123201.g001
Automated Staining and Digital Analysis of HER2
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are based on the 2007 ASCO guideline and cases withHER2/CEP17 ratio of<2.0 butHER2
copy number of6.0 are considered HER2-negative, while in the updated guideline such cases
should be considered HER2-positive. To investigate whether the new guideline would affect the
interpretation of theHER2 gene status of our validation cohort, we recalculated theHER2 gene
status of the 328 TMA cases stained with Abbott FISH, and found that in total 9 cases (2.7%)
had a different interpretation. All 9 cases involved an equivocal result, showing changes from
equivocal ratio<2.0 to negative, equivocal ratio2.0 to positive and vice versa. Most impor-
tantly, all these changes had no consequence for the therapy choice of the patients using the cri-
teria of either the old or new guideline. Therefore we assume that the new ASCO guideline will
not affect the overall conclusions in this manuscript.
Statistics
Concordance rates between different combinations of staining and analysis methods were de-
termined and Cohen’s κ statistics was performed using GraphPad QuickCals software.
Results
At first, the automated Leica FISH staining and settings of the D-Sight HER2 FISH analysis
module for digital analysis (fully automated ISH procedure) were evaluated and showed an
95% (κ = 0.94) agreement with the original Abbott FISH analysis. Only one discordant score
was found and depicted as an equivocal (< 2.0) ratio with Leica FISH versus a non-amplified
ratio with Abbott FISH (see 3x3 analysis in Table 2). However, the final interpretation was the
same, because the HER2 gene status was not amplified for both ISH procedures (see 2x2 analy-
sis in Table 2). We concluded that the automated Leica FISH staining followed by supervised-
automated digital analysis was suitable for further evaluation.
Secondly, the feasibility of using the D-Sight digital imaging platform for supervised auto-
mated analysis of the automated Leica HER2 FISH staining (fully automated ISH procedure)
was validated by comparison to the original Abbott FISH data (manual ISH procedure). In 35
TMA cases an amplification of HER2 (ratio 2.0) was identified by Leica FISH compared to
Table 2. Comparisons of automated LeicaHER2 FISH with digital analysis andmanual AbbottHER2 FISH with manual analysis in 20 full-sized
slides of tissue specimens used for TMA blocks of invasive breast cancer.
Abbott FISH (manual procedure)
Ampliﬁeda Equivocalb Non-ampliﬁedc
Leica FISH Ampliﬁed 6 0 0
(automated procedure) Equivocal 0 1 (2.0)d 1 (<2.0) d
Non-ampliﬁed 0 0 12
Overall agreement 3x3e 95.0% (κ = 0.94 (weighted))
2x2f 100%
FISH, ﬂuorescence in situ hybridization.
a ratio  2.2.
b ratio = 1.8–2.2.
c ratio <1.8.
d between brackets equivocal ratio after additional count of 20 nuclei <2.0 or 2.0.
e 3 categories (ampliﬁed / equivocal / non-ampliﬁed).
f 2 categories (ampliﬁed ratio  2.0 / non-ampliﬁed ratio <2.0).
doi:10.1371/journal.pone.0123201.t002
Automated Staining and Digital Analysis of HER2
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38 TMA cases by Abbott FISH. Overall, the agreement of Leica FISH with Abbott FISH was
98.8% (κ = 0.94; see Table 3).
Representative pictures of Leica FISH for non-amplified and amplifiedHER2 gene status
are depicted in Fig 2, with or without supervised-automated nucleus and spot detection.
Staining of Abbott FISH and Leica FISH was repeated on 3 of the 4 discordant cases using
full-sized sections of the original tumor tissue. For one case no material was left. In 2 of 3 re-
tested cases Leica FISH was concordant to Abbott FISH (amplified HER2 gene). Apparently,
the selected area with amplified HER2 gene on full-sized slides was not present on the TMA
slide stained with Leica FISH in these 2 cases. Probably sampling errors occurred in these cases
when TMA were made. The other discrepant case remained discordant between Leica (equivo-
cal ratio<2.0) and Abbott (equivocal ratio>2.0) FISH analysis.
Discrepant cases involve ISH with equivocal scores in 2 of 4 cases. Therefore, results of
these four cases were also compared to 5 other ISH staining methods as reported recently [27].
The consensus between the different ISH methods performed on these cases is low, maximally
4/7 scores were concordant per case. This indicates that cases with equivocal scores are difficult
cases for HER2 gene assessment.
Overall agreement between Leica FISH and Abbott FISH was very high after revision 99.4%
(κ = 0.97).
Finally, the use of the automated Leica HER2 FISH staining in combination with automated
analysis for assessment of the HER2 gene status in FFPET invasive breast cancer specimens in
routine clinical practice was validated on 100 resections/full-sized slides or biopsies. Results
were compared to DAKO IHC scoring and Abbott FISH data for IHC 2+ tumors. The initial
Leica FISH failure rate (no fluorescent signals were detected) was 3% (3/100). Repeated testing
of all failed Leica FISH samples was successful when adjusting the incubation time for enzyme
pretreatment from 5 min to 1 or 2 min.
The 100 slides with resection or biopsy tissue were divided into two groups. Firstly, the
HER2 gene status was evaluated in 50 selected DAKO IHC 2+ cases. The overall agreement of
Leica FISH with Abbott FISH was 93.8% (κ = 0.88; see Table 4). Three tumors were non-ampli-
fied with Leica FISH, but amplified with Abbott FISH. These cases were considered to be
Table 3. Comparisons of automated LeicaHER2 FISH with digital analysis andmanual AbbottHER2 FISH with manual analysis in tissue micro ar-
rays (TMAs) including 328 invasive breast cancer tissue specimens.
Abbott FISH (manual)
Ampliﬁeda Equivocalb Non-ampliﬁedc
Leica FISH (automated) Ampliﬁed 34 1 (1x 2.0)d 0
Equivocal 2 (2.0) d 1 (1x <2.0) d 4 (1x 2.0; 3x <2.0)d,g
Non-ampliﬁed 2g 4 (1x 2.0; 3x <2.0)d,g 280
Overall agreement 3x3e 96.0% (κ = 0.89 (weighted))
2x2f 98.8% (κ = 0.94)
FISH, ﬂuorescence in situ hybridization.
a ratio  2.2.
b ratio = 1.8–2.2.
c ratio <1.8.
d between brackets equivocal ratio after additional count of 20 nuclei <2.0 or 2.0.
e 3 categories (ampliﬁed / equivocal / non-ampliﬁed).
f 2 categories (ampliﬁed ratio  2.0 / non-ampliﬁed ratio <2.0).
g Bold characters indicate discordant results.
doi:10.1371/journal.pone.0123201.t003
Automated Staining and Digital Analysis of HER2
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discordant and reanalysis of Leica FISH confirmed amplification in 2/3 tumors. This experi-
ence prompted us to adjust the procedure for supervised-automated digital analysis in such
way that observers should perform a pre-screen of the tissue specimens at 20x magnification
followed by one at 100x magnification. Application of this workflow on the 50 consecutively
collected full-sized slides did not yield any discrepancies. The remaining discrepant case was
stained again with Abbott FISH and yielded a non-amplified score similar to Leica FISH, but
discordant to the initial result of Abbott FISH. This could be clarified by the fact that the slide
of the first Abbott FISH staining contained 3 biopsies, whereas the biopsy in the middle was
missing in the new Abbott FISH and Leica FISH staining. This case involves a tumor with het-
erogeneity for HER2 gene status. The biopsy in the middle showed amplified HER2 gene with
Abbott FISH but the two other biopsies did not.
Secondly, the Leica FISH analyses of 50 unselected tumors with different IHC scores were
all in agreement with DAKO IHC scores and Abbott FISH data for IHC 2+ tumors (see
Table 5).
Fig 2. The appearance of Leica FISHHER2 staining.Representative pictures of HER2 non-amplified invasive breast cancer specimens are shown in A)
with aHER2 (red signals) to chromosoom 17 (= CEP17; green signals) ratio<2 and C) with supervised-automated nuclei and spot detection. Examples of
HER2 amplified invasive breast cancer specimens are depicted in B) with a HER2/CEP17 ratio>2 and D) with supervised-automated nucleus and spot
detection. DAPI counterstaining and original magnification with 100x objective.
doi:10.1371/journal.pone.0123201.g002
Automated Staining and Digital Analysis of HER2
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Discussion
Recently, more standardizedHER2 gene testing has been achieved by the development of fully
automated ISH staining systems and high concordance rates were found in comparison with
manual ISH staining tests [18–20]. Standardization could further be improved by using objec-
tive scoring systems on digital FISH images developed on different platforms [24, 29]. Howev-
er, so far the combination of automated staining with automated digital analysis of invasive
breast cancer tumors has not been studied yet.
In order to investigate whether the reliability HER2 ISH testing can be improved, we com-
pared automated Leica HER2 FISH staining followed by supervised automated digital analysis
with manual Abbott FISH staining and subsequent manual analysis aimed at the use in daily
practice of a routine histopathology laboratory. We found a very high concordance (98.9%, κ =
0.94) on 328 TMA samples and 93.8% (κ = 0.88) on 50 selected IHC 2+ cases (resections or bi-
opsies). A similar performance was found in a recent study by Öhlschlegel et al. [18], compar-
ing automated Leica HER2 FISH staining and subsequent manual analysis and manual Abbott
Table 4. Comparisons of automated LeicaHER2 FISH with digital analysis andmanual AbbottHER2 FISH with manual analysis of 50 invasive
breast cancer tissue specimens (resection / biopsy) with IHC 2+ scores.
Abbott FISH (manual)
Ampliﬁeda Equivocalb Non-ampliﬁedc
Leica FISH (automated) Ampliﬁed 21 0 0
Equivocal 0 0 0
Non-ampliﬁed 3e 0 24
Overall agreement 3x3d 93.8% (κ = 0.88 (weighted))
FISH, ﬂuorescence in situ hybridization.
a ratio  2.2.
b ratio = 1.8–2.2.
c ratio <1.8.
d 3 categories (ampliﬁed / equivocal / non-ampliﬁed).
e 2x) reanalysis Leica FISH conﬁrms ampliﬁcation Abbott FISH; 1x) new staining Abbott FISH conﬁrms non-ampliﬁed score Leica FISH (ﬁrst Abbott FISH
contained 3 biopsies, whereas the biopsy in the middle is missing in the new Abbott FISH and Leica FISH). 2x missing data because no signals were
detected with Leica FISH.
doi:10.1371/journal.pone.0123201.t004
Table 5. Comparisons of LeicaHER2 FISH and DAKOHER2 IHC of 50 consecutively collected inva-
sive breast cancer tissue specimens (resection / biopsy) from routine practice.
DAKO HER2 IHC
0 1+ 2+ 3+
Leica HER2
FISH
Ampliﬁeda 0 0 2 8
Equivocalb 0 0 0 0
Non-ampliﬁedc 21 17 1 0
IHC, immunohistochemistry; FISH, ﬂuorescence in situ hybridization. 1x missing data because no signals
were detected with Leica FISH.
a ratio  2.2.
b ratio = 1.8–2.2.
c ratio <1.8.
doi:10.1371/journal.pone.0123201.t005
Automated Staining and Digital Analysis of HER2
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HER2 FISH staining followed by manual analysis. The authors reported an overall concordance
rate of 96% (κ = 0.92) and 93.3% for IHC 2+ breast cancer biopsies. These and our results stat-
ed the feasibility of automated FISH HER2 staining.
Our performance of supervised automated digital analysis (of automated stained ISH slides)
was comparable with other digital analysis systems that included automated nucleus selection
(on manually stained ISH slides). Theodosiou et al. [30] found an overall concordance of digi-
tal analysis with manual analysis of 92.8% among 100 breast cancer cases. This was in agree-
ment with data reported by Furrer et al. [24]. Concordance was 100% for non-amplified cases
and 96.9% (100% after human correction) for amplified cases. Notably, both studies recom-
mended to exclude equivocal cases, because of the suboptimal performance they encountered
when applying digital analysis on these cases. We performed digital analysis without selection
of FISH HER2 gene status, the analyses were robust and fully in concordance with the previous
manual analyses. We encountered a few difficult cases with discordant results which, in agree-
ment with the findings mentioned above, almost all were found in equivocal cases. The discrep-
ancies can be caused by different staining methods, inherent biological properties, the analysis
method or combinations of these.
Advantages for clinical practice of this automated standardizedHER2 gene testing are: 1)
further standardization of the total procedure, 2) reducing human mistakes and 3) yields ar-
chived data, which are accessible for review and objective classification. In our experience,
turnaround time and hands on time are reduced by automated testing. However, these factors
were not quantified and may by subject of future investigations. Disadvantages of FISH tech-
niques are fading of fluorescent signals, hence in time the diagnostic data are not accessible
anymore, and secondly it is not easy, sometimes impossible, to review the exact same area on
the slide of a case that was evaluated manually by one of the observers before. Using (automat-
ed) digital analysis the original diagnostic images (= coordinates) are archived and accessible
for review. By using web-based techniques images can easily be reviewed simultaneously at dif-
ferent places. In terms of transparency and quality control these are pivotal features.
As mentioned above, an advantage of supervised automated analysis is a more objective
classification of the FISH staining compared to manual analysis, because the nucleus selection
and spot counting in the areas of interest is automated and not depending on the subjectivity
of the observer. Choosing the area of interest to our opinion is not another level of subjectivity
introduced by supervised analysis but is inherent to both manual and automated methods. Be-
cause areas of heterogeneity might be present fully automated image analysis and scoring is not
possible. The system is not able to identify these areas and therefore areas of interest should be
indicated and the proposed nucleus selection confirmed by the observer. After this, automated
analysis will calculate HER2/CEP17 ratio’s for each area. This indicates that experienced ob-
servers are needed for reliable scoring of HER2 gene status. For this reason we prefer to desig-
nate the procedure as “supervised automated scoring”.
We did not evaluate the cost-effectiveness in this study. In the future, important issues to
take into consideration in this matter are that automated staining kits are more expensive than
reagents used for manual staining. Hands on time and therefore expenses for technicians to
perform FISH staining is much higher in case of a manual method. A digital analysis systems is
more expensive than a conventional microscope, but automated analysis will generate a more
objective classification compared to manual analysis. Automated analysis takes longer than
manual analysis, however digital images can be archived and are accessible for review and this
is not the case with manual analysis.
The reported method for HER2 testing is restricted to FISH analysis and does not include
automated analysis of HER2 IHC slides. Further improvements to the process of HER2 testing
could therefore be made by including automated HER2 membrane analysis of IHC slides. The
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D-Sight digital imaging platform actually has the ability to match IHC with FISH slides and is
facilitated with a HER2 IHC membrane analysis module. Validation of this analysis method
would be an opportunity to further optimize the HER2 testing procedure in the future.
Summarizing, our fully automated ISH procedure showed a similar performance as found
with a fully manual ISH procedure (> 95% concordance rates). Therefore, standardization of
the total procedure ofHER2 ISH testing could be achieved by adding supervised automated
digital analysis to automated staining. These results meet the criteria for test validation as stat-
ed by ASCO [15]. The reported method, based on supervised automated analysis of digital im-
ages, is feasible for the assessment of HER2 gene status in routine clinical practice for patients
with invasive breast cancer and yields images of high quality which are subsequently accessible
for review and transparent reporting.
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